CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Cabozantinib S-malate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02315430
NCT02315430Phase 2Completed
CompareCT.gov

A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum

National Cancer Institute (NCI)·interventional·Posted Dec 11, 2014·Updated Mar 10, 2020

In Brief

A Phase 2 clinical trial evaluating Cabozantinib S-malate and Laboratory Biomarker Analysis for Fallopian Tube Clear Cell Adenocarcinoma and 4 related conditions. Completed, enrolled 13 participants across 410 sites.

Detailed Summary

This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse. Cabozantinib-s-malate may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth and also by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsNRG Oncology

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 11, 2014
Enrollment StartApr 1, 2015
Primary CompletionFeb 9, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.6 years ago

Interventions

Cabozantinib S-malatedrug

Given PO

Laboratory Biomarker Analysisother

Optional correlative studies